January 5, 2018 / 2:24 PM / 6 months ago

BRIEF-Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof Of Mechanism For M281

Jan 5 (Reuters) - Momenta Pharmaceuticals Inc:

* MOMENTA PHARMACEUTICALS REPORTS POSITIVE TOP-LINE PHASE 1 DATA SHOWING PROOF OF MECHANISM FOR M281, AN ANTI-FCRN MONOCLONAL ANTIBODY, IN HEALTHY VOLUNTEERS

* MOMENTA PHARMACEUTICALS INC - ‍OVER 98-DAY MAD STUDY, M281 EXHIBITED NO SERIOUS ADVERSE EVENTS, WAS WELL TOLERATED​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below